PFIZER INC.

$99 for the first year includes FT newspaper Monday-Saturday, FT Digital Edition, FT Weekend, global news & analysis, expert opinion, special features, and exclusive FT analysis.

Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing significant body weight increases compared to placebo across all doses, with a 5.61% mean increase at the highest dose after 12 weeks. Ponsegromab was generally safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass at the highest dose. Pfizer plans to initiate registration-enabling studies in 2025.

Merck's stock has risen 72% in 5 years, driven by Keytruda's success, but faces uncertainty as Keytruda's patent expires in 2028. Merck forecasts 2024 revenue growth of 5-7% and seeks new blockbusters, while competition from biosimilars and alternative treatments poses risks.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.